

Identification of the Set of Genes, Including Nonannotated *morA*, under the Direct Control of ModE in *Escherichia coli*

Tatsuaki Kurata,^a Akira Katayama,^c Masakazu Hiramatsu,^a Yuya Kiguchi,^a Masamitsu Takeuchi,^a Tomoyuki Watanabe,^a Hiroshi Ogasawara,^{a,d} Akira Ishihama,^{a,b} Kaneyoshi Yamamoto^{a,b}

Department of Frontier Bioscience^a and Research Center for Micro-Nano Technology,^b Hosei University, Tokyo, Japan; Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan^c; Research Center for Human and Environmental Sciences, Shinshu University, Nagano Prefecture, Japan^d

ModE is the molybdate-sensing transcription regulator that controls the expression of genes related to molybdate homeostasis in *Escherichia coli*. ModE is activated by binding molybdate and acts as both an activator and a repressor. By genomic systematic evolution of ligands by exponential enrichment (SELEX) screening and promoter reporter assays, we have identified a total of nine operons, including the hitherto identified *modA*, *moaA*, *dmsA*, and *napF* operons, of which six were activated by ModE and three were repressed. In addition, two promoters were newly identified and direct transcription of novel genes, referred to as *morA* and *morB*, located on antisense strands of *yghW* and *torY*, respectively. The *morA* gene encodes a short peptide, MorA, with an unusual initiation codon. Surprisingly, overexpression of the *morA* 5' untranslated region exhibited an inhibitory influence on colony formation of *E. coli* K-12.

The transition metal molybdenum is essential for life. In nature, molybdenum is present in various oxidation states and transported into organisms in the form of the tetraoxoanion molybdate. In the case of *Escherichia coli*, molybdate is transported through an ABC-type transport system encoded by the *modABC* operon (1). The expression of the *modABC* operon is repressed by the molybdate-bound ModE transcription factor (2). The ModE protein functions as a homodimer and consists of two domains, the N-terminal DNA-binding domain containing a winged helix-turn-helix motif and the C-terminal molybdate-binding domain (3). Binding of molybdate to the C-terminal domain induces a conformational change of ModE so that it recognizes a palindromic sequence of its target promoters (4). In addition to repression of the molybdate transporter operon, the ModE-molybdate complex is involved in induction of three operons encoding molybdate-containing enzymes, dimethyl sulfoxide (DMSO) reductase (*dmsABC*), nitrate reductase (*napFDAGHBC*), and molybdenum cofactor synthase (*moaABCDE*) (5–7). The three known ModE-inducing targets are all involved in molybdenum metabolism and utilization. Since bacteria contain more than 50 species of the molybdate-containing enzyme, the repertoire of regulation targets of ModE could include more than the already-characterized operons.

In this study, attempts were made to identify the set of regulation targets of the *E. coli* ModE transcription factor. For this purpose, we employed the genetic systematic evolution of ligands by exponential enrichment (SELEX) screening system, which was developed for identification of the set of regulation targets recognized by DNA-binding transcription factors and was successfully used for the search of regulation targets by AscG (8), AllR (9), CitB (10), Cra (11, 12), cyclic AMP receptor protein (CRP) (13), Dan (14), LeuO (15), NemaA (16), PdhR (17), RcdA (18), PgrR (19), RstA (20), RutR (21), and TyrR (22). After the genomic SELEX screening, we identified at least 10 binding sites of the ModE-molybdate complex. Transcription *in vivo* of the predicted promoters located next to these ModE-binding sites was analyzed using reporter assays in the presence and absence of ModE. Results indicated that ModE activates six promoters (*dmsAp*, *napFp*,

moaAp, *ybhKp*, *ynfEp*, and *ecop*) and repressed the *modA* promoter. In addition, we identified two novel promoters that directed the transcription of an antisense sequence of *yghX* and *cutC* and hereby name them *morA* and *morB*, respectively. The *morA* gene encodes a small peptide, MorA, carrying an unusual N terminus of Pro, the most probable translation initiation amino acid. Interestingly, overexpression of the *morA* 5' untranslated region (UTR) interfered with *E. coli* colony formation.

MATERIALS AND METHODS

***E. coli* strains and growth conditions.** *Escherichia coli* K-12 strains BW25113 (parent strain) and JW0744 (BW25113 with *modE::Km*) were previously constructed by Baba et al. (23). WJ0101 (W3110 type A with *modE::Km*) was isolated by P1 transduction with W3110 type A (24) using the P1 lysate prepared from JW0744. These *E. coli* cells were grown at 37°C in Luria broth (LB) medium.

Purification of ModE. To construct a pModE plasmid for overproduction of His-tagged ModE, the DNA fragments were prepared by PCR using *E. coli* W3110 genome DNA as the template and a set of primer pairs, *modEF* and *modER* (for sequences, see Table S1 in the supplemental material). After digestion of the PCR-amplified fragments with NdeI and NotI, the PCR-amplified fragments were inserted into the pET21a(+) vector (Novagen) between the same restriction sites as those used for the preparation of insert DNA. The plasmids thus constructed were confirmed by DNA sequencing. pModE was transformed into *E. coli* BL21(DE3), and His-tagged ModE was overexpressed and purified as described by Yamamoto et al. (25). In brief, *E. coli* BL21(DE3) transformant was grown in 200 ml of LB medium at an optical density of 600 nm (OD₆₀₀) of 0.6, and isopropyl-β-D-thiogalactopyranoside (IPTG) was added at the final concentration of 1 mM. After 3 h of incubation, cells

Received 15 March 2013 Accepted 27 July 2013

Published ahead of print 2 August 2013

Address correspondence to Kaneyoshi Yamamoto, kanyamam@hosei.ac.jp.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JB.00304-13>.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JB.00304-13

were harvested by centrifugation, washed with a lysis buffer (50 mM Tris-HCl [pH 8.0, at 4°C] and 100 mM NaCl), and then stored at -80°C until use. For protein purification, frozen cells were suspended in 3 ml of lysis buffer containing 100 mM phenylmethylsulfonyl fluoride (PMSF). Cells were treated with lysozyme and then subjected to sonication for cell disruption. After centrifugation at 15,000 rpm for 20 min at 4°C, the resulting supernatant was mixed with 2 ml of 50% (wt/vol) Ni-nitrilotriacetic acid (NTA) agarose solution (Qiagen) and loaded onto a column. After being washed with 10 ml of the lysis buffer, the column was washed with 10 ml of washing buffer (50 mM Tris-HCl [pH 8.0, at 4°C] and 100 mM NaCl) and then 10 ml of washing buffer containing 10 mM imidazole. Proteins were eluted with 2 ml of an elution buffer (lysis buffer plus 200 mM imidazole), and peak fractions of transcription factors were pooled and dialyzed against a storage buffer (50 mM Tris-HCl [pH 7.6, at 4°C], 200 mM KCl, 10 mM MgCl₂, 0.1 mM EDTA, 1 mM dithiothreitol [DTT], and 50% [vol/vol] glycerol) and stored at -80°C until use. Protein concentration was measured by the Bradford method, and purity was checked on an SDS-PAGE gel.

Genomic SELEX. The genomic SELEX method was carried out as previously described (10, 11). In brief, the genomic DNA fragments of *E. coli* K-12 W3110 type A (24) were regenerated by PCR by using the genomic library into pBR322 as the template, a pair of primers hybridized onto plasmid vector, and *Ex Taq* DNA polymerase (TaKaRa Bio). The mixture of DNA fragments (5 pmol) and His-tagged ModE (10 pmol) were mixed in a binding buffer containing sodium molybdate (1 mM) and incubated for 30 min at 37°C. The ModE-DNA mixture was applied to an Ni-NTA column, and after unbound DNA was washed out with the binding buffer containing 10 mM imidazole, the ModE-DNA complexes were eluted with 200 mM imidazole. DNA fragments recovered from the complexes were amplified by PCR. The concentrated PCR products were purified and labeled with Cy3. The fluorescent-labeled DNAs were hybridized to a DNA microarray consisting of 43,450 probes of a 60-base-long DNA, which were designed to cover the entire *E. coli* genome at 105-bp intervals (Oxford Gene Technology, Oxford, United Kingdom). The fluorescent intensity at each probe was measured by the array scanner and was indicated as the ratio to sum of the fluorescent intensity of each spot on a slide.

Construction of the *lacZ* reporter on plasmid. To construct the *lacZ* fusion gene, pRS551 and pRS552 plasmids were used as vectors (26). The DNA fragment was amplified by PCR using the genome of the *E. coli* W3110 type A strain (24) as a template and a pair of primers, as follows: SC1_A_S and SC1_A_T for pSch1-anti-ybhK, SC1_B_S and SC1_B_T for pSch1-modA, SC2_A_S and SC2_A_T for pSch2-ybhK, SC2_B_S and SC2_B_T for pSch2-moaA, SC3_A_S-2 and SC3_A_T-2 for pSch3-antiserS, SC3_B_S-2 and SC3_B_T-2 for pSch3-dmsA, C5_A_S and SC5_A_T for pSch5-anti-ynfD, SC5_B_S and SC5_B_T for pSch5-ynfE, SC6_A_S and SC6_A_T for pSch6-torY, SC6_B_S and SC6_B_T for pSch6-anti-cutC, SC7_A_S and SC7_A_T for pSch7-napF, SC7_B_S and SC7_B_T for pSch7-eco, SC9_A_S and SC9_A_T for pSch9-yghW, SC9_B_S and SC9_B_T for pSch9-anti-yghX, SC9_B_S and SC9_B_T-E1 for pSch9-anti-yghX fusion-1, SC9_B_S and SC9_B_T-E2 for pSch9-anti-yghX fusion-2, SC9_B_S and SC9_B_T-O1R65 for pORF1-R65, SC9_B_S and SC9_B_T-O2I2 for pORF2-I2, SC9_B_S and SC9_B_T-O2I10 for pORF2-I10, SC9_B_S and SC9_B_T-O2E11 for pORF2-E11, SC9_B_S and SC9_B_T-O2P12 for pORF2-P12, SC9_B_S and SC9_B_T-O2F13 for pORF2-F13, SC9_B_S and SC9_B_T-O2Q14 for pORF2-Q14, SC9_B_S and SC9_B_T-O2C15 for pORF2-C15, SC9_B_S and SC9_B_T-O2L17 for pORF2-L17, SC9_B_S and SC9_B_T-O2G22 for pORF2-G22, SC9_B_S and SC9_B_T-O2R30 for pORF2-R30, SC9_B_S and SC9_B_T-O2M34 for pORF2-M34, SC9_B_S and SC9_B_T-O2V37 for pORF2-V37, SC9_A_S and SC9_A_T-D6 for pmorA-19, SC9_A_S and SC9_A_T-D5 for pmorA+35, SC9_A_S and SC9_A_T-D4 for pmorA+78, SC9_A_S and SC9_A_T-D3 for pmorA+95, SC9_A_S and SC9_A_T-D2 for pmorA+118, SC9_A_S and SC9_A_T-D1 for pmorA+127, SC9_A_S and SC9_A_T-E1 for pmorA+444 (see Tables S1

and S2 in the supplemental material). The PCR product was digested with BamHI and EcoRI and then ligated into pRS551 or pRS552 at the corresponding sites. The DNA sequence of insertion on plasmids was confirmed by DNA sequencing using the lac30R primer complementary to *lacZ* in a vector (for sequences, see Table S1).

Measurement of β -galactosidase activity in *E. coli*. *E. coli* cells grown in LB medium until an OD₆₀₀ of 0.3 to 0.4 were subjected to measuring β -galactosidase activity with *O*-nitrophenyl-D-galactopyranoside as described by Miller (27).

Primer extension analysis. The promoter-*lacZ* fusion plasmid was transformed into *E. coli*. Total RNA from transformants was extracted by the hot phenol method as described previously (28, 29). In brief, *E. coli* was grown in LB medium at 37°C until mid-log phase (OD₆₀₀ = 0.3 to 0.4), cells were harvested, and total RNAs were prepared with the hot phenol method. After digestion with RNase-free DNase I (TaKaRa Bio), total RNA was reextracted with phenol, precipitated with ethanol, and dissolved with RNase-free water. The concentration of total RNA was determined by measuring the absorbance at 260 nm. The purity of total RNA was checked by agarose gel electrophoresis. Primer extension analysis was performed using fluorescent-labeled probes as described previously (30). In brief, total RNA (20 μ g) and the 5'-fluorescein isothiocyanate (FITC)-labeled FITC-lac primer (for sequences, see Table S1 in the supplemental material) were mixed and the primer extension reaction was initiated by the addition of reverse transcriptase XL (Life Science). After incubation for 1 h at 50°C, DNA was extracted with phenol, precipitated with ethanol, and subjected to electrophoresis on a 6% polyacrylamide sequencing gel containing 8 M urea using DSQ-500L (Shimadzu).

DNase I footprinting analysis. Probe was amplified by PCR using a pair of primers, 5'-FITC-labeled FITC-lac and SC9_A_T (for sequences, see Table S1 in the supplemental material), pSch9-yghW plasmid as the template, and *Ex Taq* DNA polymerase. DNase I footprinting assay was carried out under the standard reaction conditions (30). In brief, 1.0 pmol each of FITC-labeled probes was incubated at 37°C for 30 min with purified ModE (0.75 to 6 pmol) in 25 μ l of binding buffer (10 mM Tris-HCl [pH 7.8], 150 mM NaCl, 3 mM magnesium acetate, 5 mM CaCl₂, and 25 μ g/ml bovine serum albumin [BSA]) containing 1 μ M Na₂MO₄. After incubation for 30 min, DNA was digested by DNase I (TaKaRa Bio) for 30 s at 25°C, and then the reaction was terminated by the addition of phenol. DNA was precipitated by ethanol, dissolved in formamide dye solution, and analyzed by electrophoresis on a DNA analyzer DSQ-500L (Shimadzu).

Western blotting. To detect MorA-LacZ fusion protein, Western blotting was performed as previously described (31). In brief, *E. coli* cells grown in LB medium were harvested, washed, and resuspended in lysis buffer (50 mM Tris-HCl [pH 8.0, at 4°C] and 100 mM NaCl) containing 100 mM PMSF. After sonication, supernatant was recovered by centrifugation, subjected to 10% SDS-PAGE, and blotted onto polyvinylidene difluoride (PVDF) membranes using an iBlot semidry transfer apparatus (Invitrogen). Membranes were first immunodetected with anti- β -galactosidase (Promega) and anti- α -subunit of RNA polymerase (NeoClone) antibodies, followed by immunodetection with a horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Nacalai Tesque) antibody and then development with a chemiluminescence kit (Nacalai Tesque). The image was analyzed with an LAS-4000 IR multicolor scanner (Fuji Film).

Affinity chromatography with APTG agarose. APTG (4-aminophenyl- β -D-thiogalactopyranoside) agarose 4B (Sigma) was used as a resin for purification of the LacZ fusion protein (32). *E. coli* transformant JW0744/pORF2-M34 was grown in 400 ml of LB medium and at an OD₆₀₀ of 1.0, and then cells were harvested by centrifugation, suspended in 12 ml of loading buffer (20 mM Tris-HCl [pH 7.4, at 4°C], 10 mM MgCl₂, 10 mM DTT, and 1.6 M NaCl) containing 100 mM PMSF. Cells were treated with lysozyme and then subjected to sonication for cell disruption. After centrifugation at 15,000 rpm for 20 min at 4°C, the resulting supernatant was loaded onto a column filled with 0.5 ml of APTG agarose 4B. After being washed with 30 ml of loading buffer, proteins were

eluted with 1 ml of an elution buffer (1 M borate and 10 mM DTT [pH 10.0, at 4°C]) four times. Elution fractions were neutralized by the addition of 1 ml of neutralization buffer (1 M Tris-HCl [pH 7.0, at 4°C]). Protein concentration was measured by the Bradford method, and purity was checked by SDS-PAGE.

Identification of proteins with a mass spectrometer. Proteins in solution were digested with 2 ng/μl proteomic-grade trypsin (Roche) in aqueous 0.8 M urea buffer at 37°C overnight. Following digestion, tryptic peptides were then analyzed using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) mass spectrometer (amaZon; Bruker). Data from mass spectrometry were analyzed using the MASCOT software (Matrix Science).

RESULTS

Search for ModE-binding sites on the *E. coli* K-12 genome. To identify the set of regulation targets of *E. coli* ModE, we performed the genomic SELEX screening. For this purpose, a mixture of *E. coli* genome DNA fragments of 200 to 300 bp in length was incubated with the purified His-tagged ModE protein in the presence of sodium molybdate. The ModE-DNA complexes formed were isolated by affinity chromatography using Ni-NTA agarose. When the genomic SELEX was carried out in the absence of molybdate, specific SELEX DNA fragments were not recovered as judged by PAGE (the DNA formed a smear on the gel, as did the original DNA mixture). After two cycles of the genomic SELEX in the presence of molybdate, however, specific DNA fragments were recovered, which formed visible bands on the PAGE gel. The DNA fragments thus isolated were cloned into pT7Blue (Novagen) for sequencing, and the resulting sequences were mapped in the *E. coli* genome by using both SELEX-clos and SELEX-chip procedures (see Materials and Methods).

For identification of the set of the binding sites by ModE, we next performed SELEX-chip analysis. The same collection of genomic SELEX fragments as used for SELEX-clos was subjected, after fluorescent labeling, to hybridization with a DNA tiling microarray (Oxford Gene Technology, Oxford, United Kingdom) (11–14). The fluorescence intensity on each spot was represented as the ratio to sum of the fluorescent intensity of each spot on an array and plotted on the corresponding position on the *E. coli* genome. Since the 60-bp-long probes are aligned along the *E. coli* genome at 105-bp intervals, approximately 300-bp-long SELEX fragments should bind to two or more consecutive probes, and we employed this criterion for identification of positive peaks with a significant intensity (Fig. 1A). A total of 10 positive peaks, SELEX-chip 1 (Sch1) to Sch10, were identified (Fig. 1A and B). Seven ModE-binding sites, Sch1, Sch2, Sch3, Sch5, Sch6, Sch7, and Sch9, were all located within intergenic spacer regions between two neighboring genes. Since the four hitherto identified ModE-binding sites were included in this list, i.e., *modABC* on Sch1, *moaABCDE* on Sch2, *dmsABC* on Sch3, and *napFDAGHBC* on Sch7, we predicted that the remaining three ModE-binding sites, Sch5, Sch6, and Sch9, are involved in regulation of neighboring genes (Fig. 1B). The rest of three ModE-binding sites were located within coding regions, Sch4 on *ydeU*, Sch8 on *gshA*, and Sch10 on *panF* (Fig. 1B). In this study, we focused detailed analysis on the ModE targets located within spacer regions.

Identification of the ModE-binding consensus sequence. Within the ModE-molybdate complex-binding sequence on the *modABC* promoter, an inverted repeat of pentanucleotides, TATAT, with a spacer of 7 nucleotides (nt), was identified by the DNase I protection assay (33). Since we identified the ModE-molybdate

binding sequences for six additional targets, we reexamined the ModE box sequence using the W-AlignACE program (34), which was successfully employed for identification of the MntR box sequence (35). After analysis of a set of 200-bp DNA sequences centered on each ModE-molybdate binding peak for six ModE target sequences (Sch1, Sch2, Sch3, Sch5, Sch6, and Sch9), we identified a conserved sequence of 24 bp in length (Fig. 1C). This revised ModE box is composed of an inverted repeat of 9 nucleotides, CGNTATATA, with a spacer of 6 nucleotides. This ModE box sequence includes the previously proposed consensus sequence of ModE binding (33). In the case of Sch7, the length of the spacer was a total of 7 nucleotides with the extent of one additional nucleotide (Fig. 1C).

Regulation of the newly identified promoters by ModE. To examine the regulation of seven ModE targets, including three newly identified promoters, we next carried out the reporter assay *in vivo* in the presence and absence of ModE. For this purpose, we constructed a set of 14 promoter-*lacZ* transcription fusions. DNA fragments (400 to 700 bp in length) containing each ModE-binding region were amplified by PCR and then ligated into the pRS551 vector (26) in front of the *lacZ* open reading frame (ORF) in both directions (Fig. 1B; see also Table S2 in the supplemental material). A total of 14 promoter-*lacZ* fusion plasmids were constructed (see Fig. 1B), each carrying the spacer region of one of the seven ModE targets in both directions. All these plasmids could be successfully transformed into both BW25113 and *modE*-deficient mutant JW0744 except for pSch1-anti-ybhT and pSch9-yghW, which we failed to transform into the *modE* mutant (for details, see below). All these transformants were subjected to LacZ assay. β-Galactosidase activity was detected for transformants harboring pSch1-*modA*, pSch2-ybhK, pSch2-*moaA*, pSch3-*dmsA*, pSch5-*ynfE*, pSch7-*napF*, and pSch7-*eco*.

The activity of three known promoters, *moaA* (pSch2-*moaA*), *dmsA* (pSch3-*dmsA*), and *napF* (pSch7-*napF*), decreased in the *modE*-deficient mutant (Fig. 2A), indicating that ModE activates these promoters. This finding agrees with previous observations (5–7). Three newly identified ModE-regulated promoters, *ybhK* (pSch2-ybhK), *ynfE* (pSch5-*ynfE*), and *eco* (pSch7-*eco*), also showed decreased activity in the *modE* mutant (Fig. 2A), indicating that these promoters are also activated by ModE. To confirm regulation of the newly identified promoters by ModE, we next performed primer extension analysis. The transcription initiation site was identified for each promoter (Fig. 2B). cDNA signals of the primer extension were detected for all three promoters, *ybhK*, *ynfE*, and *eco* in BW25113, but the signals were weak in the *modE* mutant (data not shown), implying a positive role of ModE for these promoters.

Identification of ModE-regulated promoters on the antisense strand of *cutC* and *yghX*. Among 14 promoter assay vectors, five constructs (pSch1-anti-ybhT, pSch3-anti-serS, pSch5-anti-*ynfD*, pSch6-anti-*cutC*, and pSch9-anti-yghX) carried the ModE-binding sequences that are located downstream of the respective ORF. Nevertheless, the promoter activity was detected for three constructs (pSch5-anti-*ynfD*, pSch6-anti-*cutC*, and pSch9-anti-yghX) (Fig. 2A, right), implying that these promoters transcribe the antisense sequence of the respective genes. In the case of pSch9-anti-yghX (see Fig. 1B), the ModE-binding sequence located downstream of *yghX* directed expression of LacZ, indicating the presence of a promoter on the antisense strand of *yghX*. This putative promoter directs transcription toward the opposite di-




FIG 1 Identification of ModE-binding sites on the *E. coli* genome. (A) SELEX-chip analysis for ModE was performed as described in Materials and Methods. SELEX fragments were mapped on the *E. coli* genome by using a DNA tiling microarray. The high intensity is indicated on the *E. coli* genome as an Sch number, indicating a ModE-binding site detected by SELEX-chip. (B) SELEX-chip detailed profiles on each ModE-binding position are shown with the organization of genes. At the center of each ModE-binding site, DNA fragments transcriptionally fused to the promoterless *lacZ* gene in both directions. The size of each insert is as follows: 498 bp for Sch1, 401 bp for Sch2, 613 bp for Sch3, 471 bp for Sch5, 502 bp for Sch6, 680 bp for Sch7, and 401 bp for Sch9 (see Table S2 in the supplemental material). (C) Using the set of six ModE-binding sequences identified after genomic SELEX screening, the consensus sequences reevaluated by using logo analysis (<http://weblogo.berkeley.edu/>) are shown. In the case of Sch7, an additional base was observed in the spacer of the consensus sequence.




FIG 3 The structure of the *morA* gene and construction of reporter plasmids for analysis of *morA* expression. (A) The speculated RNA sequence of the *morA* transcript was shown. Underlined segments indicate the minimum nucleotide sequence for inhibition of colony formation by overexpression of *morA* in the *modE* mutant (see Results). Two potential open reading frames, ORF1 and ORF2, and predicted terminators *rutA* and *rutB* are indicated in the *morA* RNA sequence. Actual amino acid residues to express the fused LacZ protein (see Fig. 4) are represented by black symbols in the peptide sequence of ORF2. (B) To analyze growth inhibition of *E. coli* by overexpression of *morA* (see Results), the *rrnB* terminator was followed by several lengths of *morA* genes in pRS551: -257 to +444 (pmorA+444), -257 to +144 (pSch9-yghW), -257 to +127 (pmorA+127), -257 to +118 (pmorA+118), -257 to +95 (pmorA+95), -257 to +78 (pmorA+78), -257 to +35 (pmorA+35), and -257 to -19 (pmorA-19) (see Table S2 in the supplemental material).

Organization of the ModE-regulated *morA* gene. To identify the transcription unit of the newly identified *morA* gene, we examined the length of transcript directed by the *morA* promoter. For this purpose, we constructed two types of the *morA-lacZ* transcription fusion plasmids, pSch9-anti-yghX fusion-1 (*lacZ* gene fused at +444 from the *morA* transcription start site) and pSch9-anti-yghX fusion-2 (*lacZ* gene fused at +744) (see Table S2 in the supplemental material). The β -galactosidase activity from pSch9-anti-yghX fusion-1 increased in the *modE* mutant, as in the case of original pSch9-anti-yghX (Fig. 4B). In contrast, the LacZ activity was not detected for pSch9-anti-yghX fusion-2 in both BW25113 and the *modE* mutant (Fig. 4B). Taking all this together, we predicted that *morA* transcription is terminated between +444 and +744. In this region, we found

the Rut site, *rutA* and *rutB*, for the Rho-dependent termination signal at λ tR1 (36) between +634 and +660 from the start site of *morA* transcription (Fig. 3A and 4B). In the case of λ tR1, transcription is terminated downstream, less than 100 bp from the Rut site (36). The size of the *morA* transcript was thus predicted to be \sim 744 nt in length.

Characterization of ORFs encoded by the *morA* gene. Next, we examined whether two open reading frames, ORF1 and ORF2, within the *morA* gene are expressed *in vivo*. For this purpose, we constructed a series of *morA-lacZ* protein fusion plasmids, each containing portions of the *morA* gene (Fig. 3A and Fig. 4B; see also Table S2 in the supplemental material). Since the β -galactosidase activity directed by plasmids carrying *morA*(ORF1)-*lacZ* fusions was not detected, we concluded that ORF1 was not expressed. In




FIG 4 The structure of the *morA* gene repressed by ModE. (A) *E. coli* BW25113 (lane 5) and the *modE* mutant (lane 6) harboring pSch9-anti-yghX (*morA-lacZ*) were grown in LB medium until an OD_{600} of 0.3 to 0.4, and total RNAs were prepared as described in Materials and Methods and subjected to primer extension assay. Sanger ladders are synthesized using FITC-lac primer and each plasmid as a template and A, T, G, and C ladders are indicated in lanes 1, 2, 3, and 4, respectively. (B) The transcriptionally fused *lacZ* genes of several lengths of the *morA* promoter were constructed with pRS551: 257 to +744 (pSch9-anti-yghX fusion-2), -257 to +444 (pSch9-anti-yghX fusion-1), and -257 to +144 (pSch9-anti-yghX) (see Table S2 in the supplemental material). Three *lacZ* reporter plasmids introduced into BW25113 (white bars) and the *modE*-deficient JW0744 (gray bars). The transformants were subjected to β -galactosidase assay (top). The detected Rho utilization site (Rut), *rutA* and *rutB*, is shown in the bottom panel. The numbers represent the positions in the *E. coli* MG1655 genome (GenBank no. U00096.2). (C) An FITC-labeled probe (0.04 μ M) prepared as described in Materials and Methods was incubated with 0 μ M (lane 5), 0.03 μ M (lane 6), 0.06 μ M (lane 7), 0.12 μ M (lane 8), and 0.24 μ M (lane 9) of ModE and then digested by DNase I. Sanger ladders are synthesized using FITC-lac primer and pSch9-yghW plasmid as a template (lanes 1 to 4). Bars indicate the regions protected from DNase I digestion. The numbers represent the position of protection from DNase I relative to the *morA* transcription start site, and the highlighted sequence indicates ModE-binding consensus (see Fig. 1C).

contract, *morA*(ORF2)-*lacZ* fusions directed LacZ expression in the *modE* mutant (Fig. 5), indicating that *morA*(ORF2) is expressed in the absence of repression by ModE.

To identify the initiation site of ORF2 expression, a series of *morA*(ORF2)-*lacZ* fusions were constructed, each including a junction segment between the Sch9 spacer and 3'-terminal sequence of *morA*. To our surprise, LacZ expression was not detectable in both BW25113 and the *modE* mutant for the *morA*(ORF2)-*lacZ* fusions with junction at the 2nd Ile, 10th Ile, and 11th Gln of ORF2 (Fig. 3A and 5A). Upstream from the 11th Gln of ORF2, the typical initiation codons do not exist. These results suggested that translation of ORF2 initiated at the 12th Pro, an unusual amino acid residue for translation initiation. Western blotting indicated that MorA(ORF2)-LacZ from pORF2-M32 and pORF2-P12 increased in the *modE*-deficient mutant (Fig. 5Ba). The migration of MorA(ORF2)-LacZ proteins was slightly slower than that of LacZ from the *morA-lacZ* transcription fusion gene on pSch9-anti-yghX (Fig. 5Ba).

For identification of the N-terminal residue of ORF2, we affinity purified MorA(ORF2)-LacZ and identified its N-terminal sequence. MorA(ORF2)-LacZ was expressed from pORF2-M34 (see Fig. 3A and 5B) in the *modE* mutant, subjected to APTG agarose, and then eluted with an alkaline buffer. A high level of MorA(ORF2)-LacZ and glycerol kinase (GlpK) was detected in the eluate (Fig. 5Bb). Purified MorA(ORF2)-LacZ formed a single band on a PAGE gel (Fig. 5Bb). The purified MorA(ORF2)-LacZ was digested with trypsin and subjected to LC-MS mass spectrometry. Based on the LC-MS analysis, the N-terminal proximal tryptic segment was found to carry the 20th Lys of ORF2 (Fig. 5Bb). These results indicate that MorA(ORF2) seem to be translated at the 12th Pro.

Inhibition of cell growth by overexpression of the *morA* 5' UTR. As noted above, we failed to transform the pSch9-yghW plasmid containing the spacer between *yghW* and *yghX*, including a portion of the *morA* gene into the *modE*-deficient mutant, JW0744. One possible explanation is that the expression of *morA* in the absence of repressor ModE is toxic for cell growth as measured by colony formation. Transcription of *morA* by pSch9-yghW should terminate at the *rrnB* terminator within the vector, leading to production of a 144-nucleotide-long RNA (Fig. 3B). The inhibitory effect of cell growth by pSch9-yghW transformation might be due to the expression of this truncated *morA* transcript in the absence of ModE. To examine this possibility, we constructed a series of plasmids, each carrying different lengths of the *morA* transcript (Fig. 3B). We failed to transform pmorA + 444 harboring a 444-bp sequence from the *morA* transcription initiation site, whereas pmorA-19 lacking the *morA* promoter and sequence could be transformed in the *modE* mutant. To determine the minimum region of *morA* transcript for transformation inhibition, a series of constructs, pmorA+127 (127 nt of *morA*), pmorA+118 (118 nt of *morA*), pmorA+95 (95 nt of *morA*), pmorA+78 (78 nt of *morA*), and pmorA+35 (35 nt of *morA*), was tested for transformation into the *modE* mutant (Fig. 3B). Transformants of the *modE* mutant were obtained for plasmids pmorA+78 and pmorA+35, producing short transcripts, but not with plasmids pmorA+127, pmorA+118, and pmorA+95, producing transcripts more than 95 nt long. The inhibition of transformation by a series of plasmids was also observed using WJ0101 (Δ *modE*), the derivative of W3110 (see Table S1 in the supplemental material). These results indicate that a 95-nt sequence of *morA* transcript is inhibitory for the growth of *E. coli*. The mechanism of cell growth by *morA* RNA remains to be examined.




FIG 5 Expression of short peptide MorA. (A) The protein-fused *lacZ* genes of several lengths of the potential peptide-coding region in the *morA* gene were constructed with pRS552 (vector). The amino acid residue to fuse to the LacZ protein expressed from each plasmid is as follows: 65th arginine of ORF1 in pORF1-R65, 37th valine of ORF2 in pORF2-V37, 34th methionine of ORF2 in pORF2-M34, 30th arginine of ORF2 in pORF2-R30, 22nd glycine of ORF2 in pORF2-G22, 17th leucine of ORF2 in pORF2-L17, 15th cysteine of ORF2 in pORF2-C15, 14th glutamine of ORF2 in pORF2-Q14, 13th phenylalanine of ORF2 in pORF2-F13, 12th proline of ORF2 in pORF2-P12, 11th glutamate of ORF2 in pORF2-E11, 10th isoleucine of ORF2 in pORF2-I10, and 2nd leucine of ORF2 in pORF2-I2. These *lacZ* plasmids were introduced into the BW25113 (white bars) and the *modE*-deficient JW0744 (gray bars). The transformants were subjected to β -galactosidase assay as described for Fig. 2. (Ba) *E. coli* BW25113 (odd lanes) and the *modE* mutant (even lanes) harboring pORF2-M34 (lanes 1 and 2), pORF2-P12 (lanes 3 and 4), and pSch9-anti-yghX (*morA-lacZ*) (lanes 5 and 6) were grown, and the soluble fractions of total proteins were subjected to Western blotting with antibody of both β -galactosidase and the α -subunit of *E. coli* RNA polymerase. Arrows indicate the detected proteins. (Bb) The cell lysate of *E. coli* transformant JW0744/pORF2-M34 was prepared. The resulting supernatant (lane 2 is whole extracts) was subjected to affinity chromatography with an APTG agarose 4B column. Samples were analyzed by SDS-PAGE (lane 3 is the flowthrough, lane 4 is the first elution, lane 5 is the second elution, lane 6 is the third elution, lane 7 is the fourth elution). Lane 1 represents marker proteins (Nacalai Tesque), 117 kDa, 88 kDa, 47.2 kDa, 37 kDa, 28.3 kDa, and 22.2 kDa. Arrows indicate the proteins identified by mass spectrometry. The N-terminal sequence of MorA(ORF2), predicted by analysis with LC-MS/MS, is shown.

DISCUSSION

Regulon. The essential transition metal molybdenum is present in various oxidation states in nature and transported into organisms in the form of the tetraoxoanion molybdate. The transcription factor ModE of *E. coli* is a dual regulator. In the presence of molybdate, ModE repressed transcription of the *modABC* operon encoding the transporter of molybdate (2) and activates the synthesis of molybdoenzymes and proteins for Mo metabolism, including *dmsABC* encoding dimethyl sulfoxide reductase, *napFDAGHBC* encoding nitrate reductase, and *moaABCDE* coding for molybdenum cofactor synthase (5–7) (see Fig. 2). Since bacteria contain more than 50 species of the molybdate-containing enzyme, the repertoire of regulation targets by ModE should include more than the hitherto characterized operons. In fact, after genomic SELEX screening, we identified three novel targets (*ybhK*, *ynfEFGHI*, and *eco*) in addition to four known targets (*modABC*, *dmsABC*, *napFDAGHBC*, and *moaABCDE*). The *ynfEFGHI* operon encodes the paralogue of the dimethyl sulfoxide reductase DmsABC, a molybdenum-dependent enzyme, and supports anaerobic growth in the presence of DMSO in a *dmsABC* deletion mutant (37). Another newly identified ModE target,

ybhK, encodes a homologue of YvcK, which is required for a normal cell shape and is involved in carbon metabolism in *Bacillus subtilis*, and restores the growth of the *B. subtilis yvcK* mutant (38). *eco* encodes a periplasmic protein of 142 amino acids that is a potent inhibitor of serine protease (39). The *ynfEFGHI* operon is induced under anaerobic conditions in a fumarate nitrate reduction regulator (FNR)-dependent manner (40). It is noteworthy that the ModE-activated promoters are always associated with FNR-binding sites within a distance of less than 100 bp (see Fig. 2), suggesting a cooperative function between ModE and FNR for induction of promoters by ModE.

ModE has been reported to activate *hyc* encoding a formate hydrogenlyase, *narXL* encoding a two-component regulatory system, and *deoCABD* operons encoding the deoxyribose utilization enzyme by transcriptome analysis of an *modE* and *moeA* double mutant (1, 41). Under the genomic SELEX screening conditions employed in this study, we failed to detect these promoters as ModE-binding sites, suggesting that the ModE-binding affinity to these promoters might be too low to detect *in vitro*.

By promoter assay, we detected two ModE-repressing promoters that direct transcription of antisense strands. The newly iden-

tified *morA* gene is located on the antisense strand of the *yghX* gene and is transcribed toward the opposite direction of *yghX* (see Fig. 3). Likewise, the *morB* gene is located downstream of *cutC* and directs transcription of the antisense strand of *cutC* toward the opposite direction of *cutC*. These two promoters, *morA* and *morB*, were found to be repressed by ModE, as in the case of the *modA* promoter. In concert with the repression mode, the ModE-binding site in the *modA* promoter overlaps with the binding site of RNA polymerase, suggesting competitive binding of ModE with RNA polymerase. We constructed a single-knockout mutant of both *morA* and *morB*. Growth in these strains, however, were affected neither by growth in the presence nor absence of molybdate (data not shown). Also, the intracellular level of molybdenum in both mutants did not change in comparison to that of a parent strain (data not shown).

Nature of the newly identified *morA*. Within the *morA* transcript of more than 700 nucleotides in length, there are two ORFs, *morA*(ORF1) and *morA*(ORF2), of which ORF2 was found to be expressed as detected by LacZ fusion assay and Western blotting (see Fig. 3 and 5). No homologous peptide of sequence similarity with MorA(ORF1) and MorA(ORF2) was detected by BLAST search. The *morA*(ORF2) lacks the typical organization for translation initiation. Nevertheless, the *morA*(ORF2)-*lacZ* fusion was found to be expressed (see Fig. 3 and 5). LC-MS/MS analysis of tryptic digests of MorA(ORF2) indicated the presence of a peptide with the 20th Lys at its N terminus. Translation of LacZ fusion proteins was detected when *lacZ* was fused downstream of the 12th Pro within a total of 74 codons of *morA*(ORF2). The canonical translation initiation region of *E. coli* consists of the initiation codon, a Shine-Dalgarno (SD) sequence, and an adequate spacer between them (42). Translation initiation in *E. coli* occurs on the three canonical codons, AUG (Met codon), GUG (Val codon), or UUG (Leu codon). The complete *E. coli* genomic sequence indicates that AUG, GUG, and UUG are, respectively, used for 3,542, 612, and 130 genes (43). Genes starting with noncanonical codons are rare in *E. coli*, but there are some exceptions starting with noncanonical codons, such as AUC (Ile codon) (44), AUA (Ile codon) (45), AUU (Ile codon) (46), GCG (Val codon), and UUC (Phe codon) (47). Translation initiation factor IF3 is involved in the discrimination against initiation on noncanonical codons, but this discrimination is neutralized by generating mutations within the initiator tRNAs so as to disrupt the complementary between codon-anticodon pairs (48). Up to the present time, however, translation initiation from Pro or Lys codons has not been reported. Translation from the 12th Pro codon experimentally detected may also be mediated through continuation (or *trans*-translation) of a nascent polypeptide initiated at another gene, leading to the formation of a chimeric protein. Actually, we failed to complete the translation of MorA(ORF2) *in vitro* using the reconstitution system of *E. coli* translation, PURESYSYSTEM classic II (BioComber) (data not shown), suggesting that other factors are required for the complete translation of MorA(ORF2).

The high-level expression of *morA* was found to inhibit *E. coli* cell growth as measured by colony formation. Deletion analysis of *morA* showed that the 95-nucleotide-long transcript of *morA* is enough for expression of the inhibition activity of *modE*-deficient colony formation. DNA random mutagenesis showed that a C-to-T substitution at +47 suppressed the inhibitory activity of cell growth (data not shown). Noncoding RNAs (ncRNAs) are known to play critical regulatory roles in bacteria. Most ncRNAs act as

regulators of gene expression by base pairing with mRNA of target genes (49). However, we failed to find the complementary sequences of the 95-nucleotide-long transcript of *morA* on the *E. coli* genome. For the expression of inhibitory function of some ncRNA species, the RNA chaperone protein Hfq is needed (49). We tried to isolate *modE* and *hfq* double mutants by P1 transduction but failed, implying that small amounts of transcripts under the control of ModE might be stable in the absence of Hfq. The *E. coli* transformant with the arabinose-inducible *morA* plasmid showed normal growth in LB liquid medium with and without arabinose (data not shown). It is possible that overexpression of *morA* could inhibit colony formation on solid medium but not *E. coli* growth in a liquid medium. It is not clear, however, how *morA* RNA affects *E. coli* colony formation.

ACKNOWLEDGMENTS

This work is supported by MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2008-2012.

We are grateful to Antonio Tsuneshige of Hosei University for critical reading of the manuscript. We also thank the National BioResource Project (NBRP) of Japan for providing *E. coli* strains and Ayako Kori, Mie Kanda, and Kayoko Yamada for preparation of proteins and technical support.

REFERENCES

- Self WT, Grunden AM, Hasona A, Shanmugam KT. 1999. Transcriptional regulation of molybdoenzyme synthesis in *Escherichia coli* in response to molybdenum: ModE-molybdate, a repressor of the *modABCD* (molybdate transport) operon is a secondary transcriptional activator for the *hyc* and *nar* operons. *Microbiology* 145:41–55.
- Grunden AM, Ray RM, Rosental JK, Healy FG, Shanmugam KT. 1996. Repression of the *Escherichia coli modABCD* (molybdate transport) operon by ModE. *J. Bacteriol.* 178:735–744.
- Hall DR, Gourley DG, Leonard GA, Duke EM, Anderson LA, Boxer DH, Hunter WN. 1999. The high-resolution crystal structure of the molybdate-dependent transcriptional regulator (ModE) from *Escherichia coli*: a novel combination of domain folds. *EMBO J.* 18:1435–1446.
- Schüttelkopf AW, Boxer DH, Hunter WN. 2003. Crystal structure of activated ModE reveals conformational changes involving both oxyanion and DNA-binding domains. *J. Mol. Biol.* 326:761–767.
- McNicholas PM, Rech SA, Gunsalus RP. 1997. Characterization of the ModE DNA-binding sites in the control regions of *modABCD* and *moaABCDE* of *Escherichia coli*. *Mol. Microbiol.* 23:515–524.
- McNicholas PM, Gunsalus RP. 2002. The molybdate-responsive *Escherichia coli* ModE transcriptional regulator coordinates periplasmic nitrate reductase (*napFDAGHBC*) operon expression with nitrate and molybdate availability. *J. Bacteriol.* 184:3253–3259.
- McNicholas PM, Chiang RC, Gunsalus RP. 1998. Anaerobic regulation of the *Escherichia coli dmsABC* operon requires the molybdate-responsive regulator ModE. *Mol. Microbiol.* 27:197–208.
- Ishida Y, Kori A, Ishihama A. 2009. Participation of regulator AscG of the beta-glucoside utilization operon in regulation of the propionate catabolism operon. *J. Bacteriol.* 191:6136–6144.
- Hasegawa A, Ogasawara H, Kori A, Teramoto J, Ishihama A. 2008. The transcription regulator ALLR senses both allantoin and glyoxylate and controls a set of genes for degradation and reutilization of purines. *Microbiology* 154:3366–3378.
- Yamamoto K, Matsumoto F, Oshima T, Fujita N, Ogasawara N, Ishihama A. 2008. Anaerobic regulation of citrate fermentation by CitAB in *Escherichia coli*. *Biosci. Biotechnol. Biochem.* 72:3011–3014.
- Shimada T, Fujita N, Maeda M, Ishihama A. 2005. Systematic search for the Cra-binding promoters using genomic SELEX system. *Genes Cells* 10:907–918.
- Shimada T, Yamamoto K, Ishihama A. 2011. Novel members of the Cra regulon involved in carbon metabolism in *Escherichia coli*. *J. Bacteriol.* 193:649–659.
- Shimada T, Fujita N, Yamamoto K, Ishihama A. 2011. Novel roles of cAMP receptor protein (CRP) in regulation of transport and metabolism

- of carbon sources. *PLoS One* 6:e20081. doi:10.1371/journal.pone.0020081.
14. Teramoto J, Yoshimura SH, Takeyasu K, Ishihama A. 2010. A novel nucleoid protein of *Escherichia coli* induced under anaerobic growth conditions. *Nucleic Acids Res.* 38:3605–3618.
 15. Shimada T, Yamamoto K, Ishihama A. 2009. Involvement of the leucine response transcription factor LeuO in regulation of the genes for sulfa drug efflux. *J. Bacteriol.* 191:4562–4571.
 16. Umezawa Y, Shimada T, Kori A, Yamada K, Ishihama A. 2008. The uncharacterized transcription factor YdhM is the regulator of the *nemA* gene, encoding *N*-ethylmaleimide reductase. *J. Bacteriol.* 190:5890–5897.
 17. Ogasawara H, Ishida Y, Yamada K, Yamamoto K, Ishihama A. 2007. PdhR (pyruvate dehydrogenase complex regulator) controls the respiratory electron transport system in *Escherichia coli*. *J. Bacteriol.* 189:5534–5541.
 18. Shimada T, Katayama Y, Kawakita S, Ogasawara H, Nakano M, Yamamoto K, Ishihama A. 2012. A novel regulator RcdA of the *csqD* gene encoding the master regulator of biofilm formation in *Escherichia coli*. *Microbiologyopen* 1:381–394.
 19. Shimada T, Yamazaki K, Ishihama A. 2013. Novel regulator PgrR for switch control of peptidoglycan recycling in *Escherichia coli*. *Genes Cells* 18:123–134.
 20. Ogasawara H, Hasegawa A, Kanda E, Miki T, Yamamoto K, Ishihama A. 2007. Genomic SELEX search for target promoters under the control of the PhoQP-RstBA signal relay cascade. *J. Bacteriol.* 189:4791–4799.
 21. Shimada T, Hirao K, Kori A, Yamamoto K, Ishihama A. 2007. RutR is the uracil/thymine-sensing master regulator of a set of genes for synthesis and degradation of pyrimidines. *Mol. Microbiol.* 66:744–757.
 22. Yang J, Ogawa Y, Camakaris H, Shimada T, Ishihama A, Pittard AJ. 2007. *folA*, a new member of the TyrR regulon in *Escherichia coli* K-12. *J. Bacteriol.* 189:6080–6084.
 23. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol. Syst. Biol.* 2:2006.0008.
 24. Jishage M, Ishihama A. 1997. Variation in RNA polymerase sigma subunit composition within different stocks of *Escherichia coli* strain W3110. *J. Bacteriol.* 179:959–963.
 25. Yamamoto K, Hirao K, Oshima T, Aiba H, Utsumi R, Ishihama A. 2005. Functional characterization *in vitro* of all two-component signal transduction systems from *Escherichia coli*. *J. Biol. Chem.* 280:1448–1456.
 26. Simons RW, Houtman F, Kleckner N. 1987. Improved single and multi-copy *lac*-based cloning vectors for protein and operon fusions. *Gene* 53: 85–96.
 27. Miller JH. 1972. *Experiments in molecular genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
 28. Yamamoto K, Ishihama A. 2005. Transcriptional response of *Escherichia coli* to external zinc. *J. Bacteriol.* 187:6333–6340.
 29. Yamamoto K, Ishihama A. 2005. Transcriptional response of *Escherichia coli* to external copper. *Mol. Microbiol.* 56:215–227.
 30. Ogasawara H, Yamamoto K, Ishihama A. 2011. Role of the biofilm master regulator CsgD in cross-regulation between biofilm formation and flagellar synthesis. *J. Bacteriol.* 193:2587–2597.
 31. Yamamoto K, Oshima T, Nonaka G, Ito H, Ishihama A. 2011. Induction of the *Escherichia coli cysK* gene by genetic and environmental factors. *FEMS Microbiol. Lett.* 323:88–95.
 32. Steers E, Jr, Cuatrecasas P. 1974. Isolation of beta-galactosidase by chromatography. *Methods Enzymol.* 34:350–358.
 33. Self WT, Grunden AM, Hasona A, Shanmugam KT. 2001. Molybdate transport. *Res. Microbiol.* 152:311–321.
 34. Chen X, Guo L, Fan Z, Jiang T. 2008. W-AlignACE: an improved Gibbs sampling algorithm based on more accurate position weight matrices learned from sequence and gene expression/ChIP-chip data. *Bioinformatics* 24:1121–1128.
 35. Yamamoto K, Ishihama A, Busby SJW, Grainger DC. 2011. The *Escherichia coli* K-12 MntR miniregulon includes *dps* which encodes the major stationary-phase DNA-binding protein. *J. Bacteriol.* 193:1477–1480.
 36. Chen CY, Richardson JP. 1987. Sequence elements essential for rho-dependent transcription termination at lambda trI. *J. Biol. Chem.* 262: 11292–11299.
 37. Lubitz SP, Weiner JH. 2003. The *Escherichia coli ynfEFGHI* operon encodes polypeptides which are paralogues of dimethyl sulfoxide reductase (DmsABC). *Arch. Biochem. Biophys.* 418:205–216.
 38. Görke B, Foulquier E, Galinier A. 2005. YvcK of *Bacillus subtilis* is required for a normal cell shape and for growth on Krebs cycle intermediates and substrates of the pentose phosphate pathway. *Microbiology* 151:3777–3791.
 39. McGrath ME, Gillmor SA, Fletterick RJ. 1995. Ecotin: lessons on survival in a protease-filled world. *Protein Sci.* 4:141–148.
 40. Xu M, Busby SJ, Browning DF. 2009. Activation and repression at the *Escherichia coli ynfEFGHI* operon promoter. *J. Bacteriol.* 191:3172–3176.
 41. Tao H, Hasona A, Do PM, Ingram LO, Shanmugam KT. 2005. Global gene expression analysis revealed an unsuspected *deo* operon under the control of molybdate sensor, ModE protein, in *Escherichia coli*. *Arch. Microbiol.* 184:225–233.
 42. Kozak M. 1999. Initiation of translation in prokaryotes and eukaryotes. *Gene* 234:187–208.
 43. Blattner FR, Plunkett G, III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. 1997. The complete genome sequence of *Escherichia coli* K-12. *Science* 277:1453–1462.
 44. Chalut C, Eglay JM. 1995. AUC is used as a start codon in *Escherichia coli*. *Gene* 156:43–45.
 45. Köpke AK, Leggatt PA. 1991. Initiation of translation at an AUA codon for an archaeobacterial protein gene expressed in *E. coli*. *Nucleic Acids Res.* 19:5169–5172.
 46. Romero A, García P. 1991. Initiation of translation at AUC, AUA and AUU codons in *Escherichia coli*. *FEMS Microbiol. Lett.* 68:325–330.
 47. Chattopadhyay R, Pelka H, Schulman LH. 1990. Initiation of *in vivo* protein synthesis with non-methionine amino acids. *Biochemistry* 29: 4263–4268.
 48. Meinel T, Sacerdot C, Graffe M, Blanquet S, Springer M. 1999. Discrimination by *Escherichia coli* initiation factor IF3 against initiation on non-canonical codons relies on complementarity rules. *J. Mol. Biol.* 290:825–837.
 49. Waters LS, Storz G. 2009. Regulatory RNAs in bacteria. *Cell* 136:615–628.